Добірка наукової літератури з теми "Nanoparticle-based vaccines"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Nanoparticle-based vaccines".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Nanoparticle-based vaccines"
Heuts, Jeroen, Wim Jiskoot, Ferry Ossendorp, and Koen van der Maaden. "Cationic Nanoparticle-Based Cancer Vaccines." Pharmaceutics 13, no. 5 (April 21, 2021): 596. http://dx.doi.org/10.3390/pharmaceutics13050596.
Повний текст джерелаStephens, Laura M., and Steven M. Varga. "Nanoparticle vaccines against respiratory syncytial virus." Future Virology 15, no. 11 (November 2020): 763–78. http://dx.doi.org/10.2217/fvl-2020-0174.
Повний текст джерелаMarasini, Nirmal, Mariusz Skwarczynski, and Istvan Toth. "Intranasal delivery of nanoparticle-based vaccines." Therapeutic Delivery 8, no. 3 (March 2017): 151–67. http://dx.doi.org/10.4155/tde-2016-0068.
Повний текст джерелаMarasini, Nirmal, Mariusz Skwarczynski, and Istvan Toth. "Oral delivery of nanoparticle-based vaccines." Expert Review of Vaccines 13, no. 11 (August 26, 2014): 1361–76. http://dx.doi.org/10.1586/14760584.2014.936852.
Повний текст джерелаBezbaruah, Rajashri, Vivek P. Chavda, Lawandashisha Nongrang, Shahnaz Alom, Kangkan Deka, Tutumoni Kalita, Farak Ali, Bedanta Bhattacharjee, and Lalitkumar Vora. "Nanoparticle-Based Delivery Systems for Vaccines." Vaccines 10, no. 11 (November 17, 2022): 1946. http://dx.doi.org/10.3390/vaccines10111946.
Повний текст джерелаDu, Lanying, Yang Yang, Xiujuan Zhang, and Fang Li. "Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies." Nanoscale 14, no. 4 (2022): 1054–74. http://dx.doi.org/10.1039/d1nr03831a.
Повний текст джерелаBernasconi, Valentina, Karin Norling, Marta Bally, Fredrik Höök, and Nils Y. Lycke. "Mucosal Vaccine Development Based on Liposome Technology." Journal of Immunology Research 2016 (2016): 1–16. http://dx.doi.org/10.1155/2016/5482087.
Повний текст джерелаZhang, Naru, Qianting Ji, Zezhong Liu, Kaiming Tang, Yubin Xie, Kangchen Li, Jie Zhou, et al. "Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant." Viruses 14, no. 3 (February 28, 2022): 501. http://dx.doi.org/10.3390/v14030501.
Повний текст джерелаSung, Hyo-Dong, Nayeon Kim, Yeram Lee, and Eun Jung Lee. "Protein-Based Nanoparticle Vaccines for SARS-CoV-2." International Journal of Molecular Sciences 22, no. 24 (December 14, 2021): 13445. http://dx.doi.org/10.3390/ijms222413445.
Повний текст джерелаHu, Yun, Daniel Smith, Zongmin Zhao, Theresa Harmon, Paul R. Pentel, Marion Ehrich, and Chenming Zhang. "Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine." Nanomedicine: Nanotechnology, Biology and Medicine 20 (August 2019): 102023. http://dx.doi.org/10.1016/j.nano.2019.102023.
Повний текст джерелаДисертації з теми "Nanoparticle-based vaccines"
Hu, Yun. "Development of nanoparticle based nicotine vaccines for smoking cessation." Diss., Virginia Tech, 2015. http://hdl.handle.net/10919/73574.
Повний текст джерелаPh. D.
Hanson, Melissa C. (Melissa Catherine). "Enhancement of HIV vaccine efficacy via lipid nanoparticle-based adjuvants." Thesis, Massachusetts Institute of Technology, 2014. http://hdl.handle.net/1721.1/97975.
Повний текст джерелаCataloged from PDF version of thesis. "December 2014."
Includes bibliographical references (pages 93-108).
Adjuvants are immunomodulators and/or formulations/delivery vehicles which enhance immune responses to vaccines. The lack of progress in the development of an HIV humoral vaccine is due, in part, to the absence of available adjuvants which can be sufficiently potent with minimal adverse side effects. The main goal of this thesis was to develop nanoparticles as HIV vaccine adjuvants. Building upon previous work in the Irvine lab, we determined the potency of lipid-coated microparticles was due in part to the in situ generation of antigen-displaying liposomes. Synthetic liposomes were nearly as potent as lipid-coated microparticles, but with a 10-fold greater antigen conjugation efficiency. We subsequently optimized unilamellar liposomes as delivery vehicles for surface-displayed HIV antigens. For vaccines with a recombinant gpl20 monomer (part of the HIV envelope trimer), immunization at 0 and 6 weeks with 65 nm or 150 nm diameter liposomes with 7.5 pmol gpl20 was found to induce strong anti-gp120 titers which competed with the broadly-neutralizing antibody VRC01. The second HIV antigen used was a peptide derived from the membrane proximal external region (MPER) of the gp41 protein. High-titer IgG responses to MPER required the presentation of MPER on liposomes and the inclusion of molecular adjuvants such as monophosphoryl lipid A. Anti-MPER humoral responses were further enhanced optimizing the MPER density to a mean distance of -10-15 nm between peptides on the liposomes surfaces. Lastly, we explored the adjuvant potential of cyclic dinucleotides (CDNs) with MPER liposome vaccines. Encapsulation of CDN in PEGylated liposomes enhanced its accumulation in draining lymph nodes (dLNs) 15-fold compared to unformulated cyclic dinucleotide. Liposomal CDN robustly induced type I interferon in dLNs, and promoted durable antibody titers comparable to a 30-fold larger dose of unformulated CDN without the systemic toxicity of the latter. This work defines several key properties of liposome formulations that promote durable, high-titer antibody responses against HIV antigens and demonstrates the humoral immunity efficacy of nanoparticulate delivery of cyclic dinucleotides, which is an approach broadly applicable to small molecule immunomodulators of interest for vaccines and immunotherapy.
by Melissa C. Hanson.
Ph. D.
Patel, Bindi Patel. "Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer." Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1523873757595623.
Повний текст джерелаDhakal, Santosh. "Development and Evaluation of Nanoparticle-based Intranasal Inactivated Influenza Virus Vaccine Candidates in Pigs." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1529829066502348.
Повний текст джерелаHan, Yi. "Development and Evaluation of Mucoadhesive Chitosan Nanoparticle-based Salmonella Vaccine for Oral Delivery in Broiler Birds." The Ohio State University, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=osu1587571015936815.
Повний текст джерелаZhao, Zongmin. "Factors that Affect the Immunogenicity of Lipid-PLGA Nanoparticle-Based Nanovaccines against Nicotine Addiction." Diss., Virginia Tech, 2017. http://hdl.handle.net/10919/88033.
Повний текст джерелаPHD
Yang, Fan [Verfasser], and Frank [Akademischer Betreuer] Rösl. "Re-engineering a Nanoparticle Human Papillomavirus Prophylactic Vaccine Antigen Based on the Minor Capsid Protein L2 / Fan Yang ; Betreuer: Frank Rösl." Heidelberg : Universitätsbibliothek Heidelberg, 2020. http://d-nb.info/121816798X/34.
Повний текст джерелаYi-WenLiu and 劉怡彣. "Development of a biodegradable nanoparticle based vaccine for Clostridium difficile infection." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/43479618648331768996.
Повний текст джерела國立成功大學
微生物及免疫學研究所
104
Clostridium difficile is now considered to be one of the major causes of infectious diarrhea in healthcare systems worldwide. C. difficile infection is believed to be a toxin-mediated intestinal disease caused mainly by two large exotoxins, toxins A and B. In this study, we constructed a non-toxic recombinant protein, rTcdB, which consists of residues 1852-2363 of Toxin B receptor binding domain as a potential vaccine candidate. rTcdB was encased in nanoparticles (NPs) composed of γ-PGA and chitosan, which are made of natural materials, biodegradable, non-toxic and able to induce a high degree of immune response. Moreover, the NPs were recently reported as a mucosal adjuvant; it could induce a strong mucosal immunity in the gastrointestinal tract. We compared intraperitoneal injection and mucosal vaccination regimens and found that both methods provided mice full protection from lethal dose of C. difficile spore challenge. Protection was associated with high levels of toxin-neutralizing antibodies, and the rTcdB-encapsulating NPs elicited longer-lasting antibody responses than rTcdB with the conventional adjuvant, aluminum hydroxide. These results suggest that rTcdB is highly immunogenic when encapsulated by the safe and potent vaccine adjuvant NPs. In conclusion, this study demonstrates that prophylactic parenteral or oral vaccination with rTcdB-encapsulating NPs can provide protection from C. difficile infection.
Частини книг з теми "Nanoparticle-based vaccines"
Bharali, Dhruba J., Shaker A. Mousa, and Yasmin Thanavala. "Micro- and Nanoparticle-Based Vaccines for Hepatitis B." In Advances in Experimental Medicine and Biology, 415–21. New York, NY: Springer New York, 2007. http://dx.doi.org/10.1007/978-0-387-72005-0_44.
Повний текст джерелаMadkour, Loutfy H. "Application of Carbon Nanotubes in Cancer Vaccines as Drug Delivery Tools." In Nanoparticle-Based Drug Delivery in Cancer Treatment, 275–310. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003229674-9.
Повний текст джерелаIlyinskii, Petr O., and Lloyd P. M. Johnston. "Nanoparticle-Based Nicotine Vaccine." In Biologics to Treat Substance Use Disorders, 249–78. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-23150-1_14.
Повний текст джерелаZubair, Swaleha, Asim Azhar, Nazoora Khan, Ejaj Ahmad, Mohd Ajmal, and Mohammad Owais. "Nanoparticle-Based Mycosis Vaccine." In Methods in Molecular Biology, 169–211. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7104-6_13.
Повний текст джерелаAkagi, Takami, Masanori Baba, and Mitsuru Akashi. "Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine." In Polymers in Nanomedicine, 31–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/12_2011_150.
Повний текст джерелаDiaz-Arévalo, Diana, and Mingtao Zeng. "Nanoparticle-based vaccines." In Nanopharmaceuticals, 135–50. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-817778-5.00007-5.
Повний текст джерелаFujita, Y., and H. Taguchi. "Nanoparticle-Based Peptide Vaccines." In Micro and Nanotechnology in Vaccine Development, 149–70. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-323-39981-4.00008-7.
Повний текст джерелаSaravanan, Muthupandian, Kebret Duche, Tsehaye Asmelash, Araya Gebreyesus, Anima Nanda, and Selvaraj Arokiyaraj. "Nanomedicine as a Newly Emerging Approach Against Multidrug-Resistant Tuberculosis (MDR-TB)." In Integrating Biologically-Inspired Nanotechnology into Medical Practice, 50–73. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0610-2.ch003.
Повний текст джерелаSaravanan, Muthupandian, Kebret Duche, Tsehaye Asmelash, Araya Gebreyesus, Anima Nanda, and Selvaraj Arokiyaraj. "Nanomedicine as a Newly Emerging Approach Against Multidrug-Resistant Tuberculosis (MDR-TB)." In Biomedical Engineering, 941–60. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-3158-6.ch041.
Повний текст джерелаKrishna Rao, Balaga Venkata, Aditi Pradhan, Sneha Singh, and Abhimanyu Dev. "An Overview on Nanoparticulate Drug Delivery System for its Specific and Targeted Effects in Various Diseases." In Nanoparticles and Nanocarriers-Based Pharmaceutical Formulations, 55–92. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815049787122010005.
Повний текст джерелаТези доповідей конференцій з теми "Nanoparticle-based vaccines"
Steinmetz, Nicole F., Jonathan K. Pokorski, Steven N. Fiering, P. Jack Hoopes, Sourabh Shukla, Oscar A. Ortega-Rivera, Steven King, and Cyril J. Empig. "Abstract S05-02: Plant viral nanoparticle-based adjuvants for cancer immunotherapy and COVID-19 vaccines." In Abstracts: AACR Virtual Meeting: COVID-19 and Cancer; February 3-5, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1557-3265.covid-19-21-s05-02.
Повний текст джерелаKim, Hyunjoon, Peter Larson, Tamara A. Kucaba, Katherine A. Murphy, David M. Ferguson, Thomas S. Griffith, and Jayanth Panyam. "Abstract 718: Nanoparticle-based tumor cell lysate vaccine for cancer immunotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-718.
Повний текст джерелаNiu, Lin, Leonard Chu, Kris Hansen, and Jayanth Panyam. "Abstract A51: Intradermal delivery of polymeric nanoparticle based vaccine formulation using a hollow microneedle system." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-a51.
Повний текст джерелаNeuhaus, Vanessa, Katharina Schwarz, Wolfgang Koch, Katherina Sewald, Vidadi Yusibov, and Armin Braun. "Immunotoxic Characterization Of A Nanoparticle-Based Inhalable Influenza Vaccine In Murine And Human Precision Cut Lung Slices." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2246.
Повний текст джерела